Grifols, S.A. (NASDAQ:GRFS) Sees Significant Increase in Short InterestDefense World · Oct 16, 2026
Head to Head Analysis: Creative Medical Technology (NASDAQ:CELZ) versus Grifols (NASDAQ:GRFS)Defense World · Sep 30, 2026
GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?Zacks Investment Research · Sep 24, 2026
Grifols says Canada plasma license suspension has no impactReuters · Sep 24, 2026
Grifols: Better Plasma Economics Can Unlock A Discounted EquitySeeking Alpha · Sep 16, 2026
Analyzing Gilead Sciences (NASDAQ:GILD) & Grifols (NASDAQ:GRFS)Defense World · Sep 11, 2026Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 28, 2026 | $0.27 | $0.25 | Miss |
| May 7, 2026 | $0.16 | $0.17 | Beat |
| Feb 26, 2026 | $0.29 | $0.29 | Miss |
| Nov 4, 2025 | $0.24 | $0.21 | Miss |
| Jul 29, 2025 | $0.23 | $0.19 | Miss |
| May 12, 2025 | $0.15 | $0.13 | Miss |